Cited by 111SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

Open access

Sievers, Benjamin L., Chakraborty, Saborni, Xue, Yong, Gelbart, Terri, Gonzalez, Joseph C., Cassidy, Arianna G., Golan, Yarden, Prahl, Mary, Gaw, Stephanie L., Arunachalam, Prabhu S., Blish, Catherine A., Boyd, Scott D., Davis, Mark M., Jagannathan, Prasanna, Nadeau, Kari C., Pulendran, Bali, Singh, Upinder, Scheuermann, Richard H., Frieman, Matthew B., Vashee, Sanjay, Wang, Taia T., Tan, Gene S.·2022·Science Translational Medicine

DOI 10.1126/scitranslmed.abn7842PMC PMC8891085

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that have mutations associated with increased transmission and antibody escape have arisen over the course of the current pandemic. Although the current vaccines have largely been effective against past variants, the number of mutations found on the Omicron (B.1.1.529) spike protein appear to diminish the protection conferred by preexisting immunity. Using vesicular stomatitis virus (VSV) pseudoparticles expressing the spike protein of several SARS-CoV-2 variants, we evaluated the magnitude and breadth of the neutralizing antibody response over time in individuals after infection and in mRNA-vaccinated individuals. We observed that boosting increases the magnitude of the antibody response to wild-type (D614), Beta, Delta, and Omicron variants; however, the Omicron variant was the most resistant to neutralization. We further observed that vaccinated healthy adults had robust and broad antibody responses, whereas responses may have been reduced in vaccinated pregnant women, underscoring the importance of learning how to maximize mRNA vaccine responses in pregnant populations. Findings from this study show substantial heterogeneity in the magnitude and breadth of responses after infection and mRNA vaccination and may support the addition of more conserved viral antigens to existing SARS-CoV-2 vaccines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.abn7842

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1. Plasma neutralizing titers against variants of concern wane over time in samples from an outpatient COVID-19 infection cohort. (A) Study participants were enrolled (day 0) within three days of a positive SARS-CoV-2 PCR test (+PCR). Longitudinal plasma samples from day 28 (n=23), day 210 (n=23) and day 300 (n=8) were assessed against D614, Delta, Beta and Omicron. (B) The kinetics of half-maximal SARS-CoV-2 pseudovirus neutralizing titers (pNT50) over time are shown. Dotted lines indicate baseline mean pNT50 obtained from seronegative subjects. Solid lines connect samples from the same participant. (C) Mean pNT50 values are shown across study time-points of all 4 pseudovirus variants. Values that were significantly different from D614 at each time point are marked with a star. (D) Ratios of pNT50 values of the indicated variants of concern over D614 pNT50 at each study time point are shown. Horizontal bars indicate median values. p values in (B to D) were calculated using mixed effects analysis with Geisser-Greenhouse correction and Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01.CC BY · PubMed Central

Fig. 2. Plasma neutralizing titers against variants of concern increase after mRNA vaccination in a cohort of pregnant women. (A) Samples collected from a cohort of vaccinated pregnant women at baseline (n=9) and after 2 doses of mRNA vaccine (n=33) were assessed for neutralizing antibody against 4 SARS-CoV-2 pseudovirus strains. (B) pNT50 values of paired samples at baseline and after 2 doses of mRNA vaccine (PD2) are presented. Samples from 9 participants from whom paired samples were available are shown; fold change of mean titers between the 2 time-points are indicated. (C) pNT50 values against the 4 SARS-CoV-2 pseudoviral variants were measured in samples collected after 2 doses of mRNA vaccine. Fold reduction of mean pNT50 compared to D614 are indicated for each variant. (D) Ratios of pNT50 values of the indicated variants of concern over D614 pNT50 are shown. Horizontal bars in (C and D) indicate median values. p values in (C and D) were calculated using repeated measures one way-ANOVA with Geisser Greenhouse correction and with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ****P < 0.0001.CC BY · PubMed Central

Fig. 3. Plasma neutralizing titers against variants of concern are increased after a third dose of mRNA vaccine in a cohort of healthcare workers. (A) Samples were collected from a cohort of healthcare workers who received 2 doses of Pfizer vaccine 21 days apart and received a 3rd dose 242 to 324 days after the first dose. Antibody titers were assessed at 28 and 210 days post dose 1 (PD1), and 7 days and 21 to 28 days post dose 3 (PD3). (B) The kinetics of pNT50 values against D614, Delta, Beta, and Omicron are shown. Dotted lines indicate baseline mean pNT50 obtained from seronegative subjects. Solid lines connect samples from the same participant (C) pNT50 values (left panel) and ratios of pNT50 of the indicated variants of concern over D614 pNT50 (right panel) are shown for samples collected 7 days after 3rd dose of vaccine. (D) pNT50 values (left panel) and ratios of pNT50 of the indicated variants of concern over D614 pNT50 (right panel) are shown for samples collected 21 to 28 days after 3rd dose of vaccine. Horizontal bars in (C and D) indicate median values. p values in (C) were calculated using repeated measures one way-ANOVA with Geisser Greenhouse correction and with Tukey’s multiple comparisons test. p values in (B and D) were calculated using mixed effects analysis with Geisser-Greenhouse correction and Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome
Gibson, D. G., Glass, J. I., Lartigue, C., Noskov, V. N., Chuang, R.-Y., Algire, M. A., Benders, G. A., Montague, M. G., Ma, L., Moodie, M. M., et al. (2010) · Science · doi:10.1126/science.1190719 · Cited by 2,638
Self-citation
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection
Villar, J., Ariff, S., Gunier, R. B., Thiruvengadam, R., Rauch, S. A., Kholin, K. A. M., Roggero, P., Prefumo, F., do Vale, M. S., Cardona–Pérez, J. A., et al. (2021) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2021.1050 · Cited by 1,340
SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
Karim, S. S. A., & Karim, Q. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02758-6 · Cited by 1,302
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031364 · Cited by 1,246
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01540-1 · Cited by 1,163
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,070

Show all 35 references

Research works printed but not linked: 1

10.1038/s41586-021-04387-1 · DOI · Paper page

Sorted by citations

SARS-CoV-2 Omicron variant: recent progress and future perspectives
Fan, Y., Li, X., Zhang, L., Wan, S., Zhang, L., & Zhou, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00997-x · Cited by 599
Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
Khandia, R., Singhal, S., Alqahtani, T., Kamal, M. A., El-Shall, N. A., Nainu, F., Desingu, P. A., & Dhama, K. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112816 · Cited by 308
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
Shapira, T., Monreal, I. A., Dion, S. P., Buchholz, D. W., Imbiakha, B., Olmstead, A. D., Jager, M. C., Désilets, A., Gao, G., Martins, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04661-w · Cited by 248
Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance
Shaqra, A. M., Zvornicanin, S. N., Huang, Q. Y. J., Lockbaum, G. J., Knapp, M. S., Tandeske, L., Bakan, D. T., Flynn, J. M., Bolon, D. N. A., Moquin, S. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31210-w · Cited by 128
SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
Richardson, S. I., Madzorera, V. S., Spencer, H., Manamela, N. P., van der Mescht, M. A., Lambson, B. E., Oosthuysen, B., Ayres, F., Makhado, Z., Moyo-Gwete, T., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.03.029 · Cited by 119
SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance
Guo, Y., Han, J., Zhang, Y., He, J., Yu, W., Zhang, X., Wu, J., Zhang, S., Kong, Y., Guo, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877101 · Cited by 118
Durability of immune responses to mRNA booster vaccination against COVID-19
Arunachalam, P. S., Lai, L., Samaha, H., Feng, Y., Hu, M., Hui, H. S.-Y., Wali, B., Ellis, M. L., Davis-Gardner, M. E., Huerta, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167955 · Cited by 105
Self-citation
Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms
Atyeo, C. G., Shook, L. L., Brigida, S. M., Guzman, R. M. D., Demidkin, S., Muir, C., Akinwunmi, B. O., Baez, A. M., Sheehan, M. L., McSweeney, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31169-8 · Cited by 100
Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant
Schubert, M., Bertoglio, F., Steinke, S., Heine, P. A., Ynga-Durand, M. A., Maaß, H., Sammartino, J. C., Cassaniti, I., Zuo, F., Du, L., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02312-5 · Cited by 92
Combining L-Arginine with vitamin C improves long-COVID symptoms: The LINCOLN Survey
Izzo, R., Trimarco, V., Mone, P., Aloè, T., Marzani, M. C., Diana, A., Fazio, G., Mallardo, M., Maniscalco, M., Marazzi, G., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106360 · Cited by 94
Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8+ T cell responses post SARS-CoV-2 infection
Gao, F., Mallajosyula, V. V. A., Arunachalam, P. S., van der Ploeg, K., Manohar, M., Röltgen, K., Yang, F., Wirz, O. F., Hoh, R. A., Haraguchi, E., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.03.005 · Cited by 87
Self-citation
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates
Mohapatra, R. K., Tiwari, R., Sarangi, A. K., Islam, M. R., Chakraborty, C., & Dhama, K. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27633 · Cited by 83
Omicron variant: Current insights and future directions
Rana, R., Kant, R., Huirem, R. S., Bohra, D., & Ganguly, N. K. (2022) · Microbiological Research · doi:10.1016/j.micres.2022.127204 · Cited by 83
Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy
Prahl, M. K., Golan, Y., Cassidy, A. G., Matsui, Y., Li, L., Alvarenga, B. D., Chen, H., Jigmeddagva, U., Lin, C. Y., Gonzalez, V. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32188-1 · Cited by 78
Self-citation
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Amanatidou, E., Gkiouliava, A., Pella, E., Serafidi, M., Tsilingiris, D., Vallianou, N. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100180 · Cited by 78
Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth
Wimmers, F., Burrell, A. R., Feng, Y., Zheng, H., Arunachalam, P. S., Hu, M., Spranger, S., Nyhoff, L. E., Joshi, D., Trisal, M., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.044 · Cited by 77
Self-citation
Evolution of the SARS-CoV-2 Omicron spike
Parsons, R., & Acharya, P. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113444 · Cited by 79
An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses
Aunins, E., Phan, A. T., Alameh, M., Dwivedi, G., Cruz-Morales, E., Christian, D. A., Tam, Y. K., Bunkofske, M. E., Zabala-Peñafiel, A., O’Dea, K. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.ads1328 · Cited by 75
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
Lee, I., Sun, C., Wu, P., Lan, Y.-H., Wang, I.-H., Liu, W., Yuan, J. P., Chang, Y.-W., Tseng, S.-C., Tsung, S.-I., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00830-1 · Cited by 66
Vaccination and immunotherapies in neuroimmunological diseases
Winkelmann, A., Loebermann, M., Barnett, M. H., Hartung, H., & Zettl, U. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00646-5 · Cited by 64
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
Assawakosri, S., Kanokudom, S., Suntronwong, N., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Duangchinda, T., Chantima, W., Pakchotanon, P., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac092 · Cited by 60
COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy
Kumar, D., Verma, S., & Mysorekar, I. U. (2022) · Translational research · doi:10.1016/j.trsl.2022.08.007 · Cited by 59
Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination
Fumagalli, V., Ravà, M., Marotta, D., Lucia, P. D., Bono, E. B., Giustini, L., Leo, F. D., Casalgrandi, M., Monteleone, E., Mouro, V., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01787-z · Cited by 61
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
Rénia, L., Goh, Y. S., Rouers, A., Bert, N. L., Chia, W. N., Chavatte, J., Fong, S., Chang, Z. W., Zhuo, N. Z., Tay, M. Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32312-1 · Cited by 62
SARS‐CoV‐2 and its variants of concern including Omicron: A never ending pandemic
Mohapatra, R. K., Kuppili, S., Suvvari, T. K., Kandi, V., Behera, A., Verma, S., Kudrat‐E‐Zahan, Biswal, S. K., AL-Noor, T. H., El‐ajaily, M. M., et al. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14035 · Cited by 59
Challenges of the Omicron (B.1.1.529) Variant and Its Lineages: A Global Perspective
Mohapatra, R. K., Kandi, V., Verma, S., & Dhama, K. (2022) · ChemBioChem · doi:10.1002/cbic.202200059 · Cited by 51
Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine
Arunachalam, P. S., Feng, Y., Ashraf, U., Hu, M., Walls, A. C., Edara, V. V., Zarnitsyna, V. I., Aye, P. P., Golden, N., Miranda, M. C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4130 · Cited by 53
Self-citation
SARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis
McGrath, M. E., Xue, Y., Dillen, C. A., Oldfield, L. M., Assad-Garcia, N., Zaveri, J., Singh, N., Baracco, L., Taylor, L. J., Vashee, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204717119 · Cited by 49
Self-citation
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases
Dayam, R. M., Law, J. C., Goetgebuer, R., Chao, G. Y. C., Abe, K. T., Sutton, M., Finkelstein, N. Y., Stempak, J. M., Pereira, D. A. S., Croitoru, D. O., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159721 · Cited by 48
mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
Lee, H., Knabl, L., Moliva, J. I., Knabl, L., Werner, A. P., Boyoglu-Barnum, S., Kapferer, S., Pateter, B., Walter, M., Sullivan, N. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110680 · Cited by 47
Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
Liu, Y., Wang, Z., Zhuang, X., Zhang, S., Chen, Z., Zou, Y., Sheng, J., Li, T., Tai, W., Yu, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37926-7 · Cited by 43
COVID-19 and vaccination: myths vs science
Chavda, V. P., Chen, Y., Dave, J. B., Chen, Z., Chauhan, S. C., Yallapu, M. M., Uversky, V. N., Bezbaruah, R., Patel, S., & Apostolopoulos, V. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2114900 · Cited by 37
Association of Infection with Different SARS-CoV-2 Variants during Pregnancy with Maternal and Perinatal Outcomes: A Systematic Review and Meta-Analysis
Deng, J., Ma, Y., Liu, Q., Du, M., Liu, M., & Liu, J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192315932 · Cited by 37
Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
Shi, W., Wang, L., Zhou, T., Sastry, M., Yang, E. S., Zhang, Y., Chen, M., Chen, X., Choe, M., Creanga, A., et al. (2022) · Structure · doi:10.1016/j.str.2022.06.004 · Cited by 37
Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients
Lee, H., Knabl, L., Walter, M. F., Knabl, L., Dai, Y., Füßl, M., Caf, Y., Jeller, C., Knabl, P., Obermoser, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.916686 · Cited by 32
Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
Xu, A., Hong, B., Lou, F., Wang, S., Li, W., Shafqat, A., An, X., Zhao, Y., Song, L., Tong, Y., et al. (2022) · MedComm · doi:10.1002/mco2.172 · Cited by 30
Medicinal chemistry insights into antiviral peptidomimetics
Ding, D., Xu, S., da Silva‐Júnior, E. F., Liu, X., & Zhan, P. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103468 · Cited by 28
Marine natural products and human immunity: novel biomedical resources for anti-infection of SARS-CoV-2 and related cardiovascular disease
Hu, C. (2024) · Natural Products and Bioprospecting · doi:10.1007/s13659-024-00432-4 · Cited by 24
Sialylated IgG induces the transcription factor REST in alveolar macrophages to protect against lung inflammation and severe influenza disease
Chakraborty, S., Cheng, B. Y.-L., Edwards, D. L., González, J. C., Chiu, D. K., Zheng, H., Scallan, C., Guo, X., Tan, G. S., Coffey, G., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.10.002 · Cited by 24
Self-citation
Immunological imprinting of humoral immunity to SARS-CoV-2 in children
Dowell, A. C., Lancaster, T., Bruton, R. K., Ireland, G., Bentley, C., Sylla, P., Zuo, J., Scott, S., Jadir, A., Begum, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39575-2 · Cited by 25
Omicron: A SARS‐CoV‐2 variant of real concern
Gattinger, P., Tulaeva, I., Borochova, K., Kratzer, B., Trapin, D., Kropfmüller, A., Pickl, W. F., & Valenta, R. (2022) · Allergy · doi:10.1111/all.15264 · Cited by 21
MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
Tai, W., Zheng, J. H., Zhang, X., Shi, J., Wang, G., Guan, X., Zhu, J., Perlman, S. M., & Du, L. (2023) · Virus Research · doi:10.1016/j.virusres.2023.199156 · Cited by 21
Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants
Chang, M., Ke, H., Coherd, C. D., Wang, Y., Mashima, K., Kastrunes, G. M., Huang, C., & Marasco, W. A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104025 · Cited by 20
Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics
Pérez‐Vargas, J., Shapira, T., Olmstead, A. D., Villanueva, I., Thompson, C. A. H., Ennis, S., Gao, G., Guzman, J. D., Williams, D. E., Wang, M., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105484 · Cited by 19
Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination
Nogimori, T., Suzuki, K., Masuta, Y., Yagoto, M., Ikeda, M., Katayama, Y., Washizaki, A., Kanda, H., Takada, M., Minami, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1081047 · Cited by 19
Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants
Emmenegger, M., Fiedler, S., Brugger, S. D., Devenish, S. R. A., Morgunov, A. S., Ilsley, A., Ricci, F., Malik, A. Y., Scheier, T., Batkitar, L., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104766 · Cited by 20
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern
Shi, J., Wang, G., Zheng, J. H., Verma, A. K., Guan, X., Malisheni, M. M., Geng, Q., Li, F., Perlman, S. M., & Du, L. (2022) · npj Vaccines · doi:10.1038/s41541-022-00580-z · Cited by 18
SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
Hederman, A. P., Natarajan, H., Heyndríckx, L., Ariën, K. K., Wiener, J. A., Wright, P. F., Bloch, E. M., Tobian, A. A. R., Redd, A. D., Blankson, J. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40960-0 · Cited by 19
Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial
Gatechompol, S., Kittanamongkolchai, W., Ketloy, C., Prompetchara, E., Thitithanyanont, A., Jongkaewwattana, A., Buranapraditkun, S., Alameh, M.-G., Ubolyam, S., Sophonphan, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01271-0 · Cited by 15
Landscape of the RBD-specific IgG, IgM, and IgA responses triggered by the inactivated virus vaccine against the Omicron variant
Xue, J.-B., Lai, D., Jiang, H., Qi, H., Guo, S., Zhu, Y., Xu, H. Y., Zhou, J., & Tao, S. (2022) · Cell Discovery · doi:10.1038/s41421-022-00380-8 · Cited by 15
Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models
Andrade, V. M., Maricic, I., Kalia, R., Jachimowicz, L. A., Bedoya, O., Kulp, D. W., Humeau, L. M. P. F., & Smith, T. R. F. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2281733 · Cited by 15
mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern
Wang, G., Shi, J., Verma, A. K., Guan, X., Perlman, S. M., & Du, L. (2022) · iScience · doi:10.1016/j.isci.2022.105690 · Cited by 14
Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation
Nguyen, H. V., Nguyen, H. L., Lan, P. D., Thai, N. Q., Sikora, M., & Li, M. S. (2023) · Chemical Society Reviews · doi:10.1039/d1cs01170g · Cited by 15
mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern
Wang, H., Chen, Z., Wang, Z., Li, J., Yan, Z., Yuan, J., Zhu, A., Chen, L., Liu, Y., Hu, C., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2081616 · Cited by 13
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
Magaret, C. A., Li, L., deCamp, A. C., Rolland, M., Juraska, M., Williamson, B. D., Ludwig, J., Molitor, C., Benkeser, D. C., Luedtke, A. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46536-w · Cited by 14
Immunization with a Prefusion SARS-CoV-2 Spike Protein Vaccine (RBMRNA-176) Protects against Viral Challenge in Mice and Nonhuman Primates
Ma, Q., Li, R., Guo, J., Li, M., Ma, L., Dai, J., Shi, Y., Dai, J., Huang, Y., Dai, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10101698 · Cited by 13
Persistent immune and clotting dysfunction detected in saliva and blood plasma after COVID-19
Jang, H., Choudhury, S. N., Yu, Y., Sievers, B. L., Gelbart, T., Singh, H., Rawlings, S. A., Proal, A. D., Tan, G. S., Qian, Y., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17958 · Cited by 12
Self-citation
Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
Zang, J., Yin, Y., Xu, S., Qiao, W., Liu, Q., Lavillette, D., Zhang, C., Wang, H., & Huang, Z. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908478 · Cited by 11
An mRNA vaccine candidate for the SARS-CoV-2 Omicron variantPreprint
Zang, J., Zhang, C., Yin, Y., Xu, S., Qiao, W., Lavillette, D., Wang, H., & Huang, Z. W. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.07.479348 · Cited by 10
Overview of COVID-19 Infection, Treatment, and Prevention in Children
Kao, C. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020424 · Cited by 9
Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older
Saiag, E., Alcalay, Y., Marudi, O., Orr‐Urtreger, A., & Hagin, D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.12.035 · Cited by 10
Nonself Mutations in the Spike Protein Suggest an Increase in the Antigenicity and a Decrease in the Virulence of the Omicron Variant of SARS-CoV-2
Otaki, J. M., Nakasone, W., & Nakamura, M. (2022) · COVID · doi:10.3390/covid2030029 · Cited by 9
Anti‐Coronaviral Nanocluster Restrain Infections of SARS‐CoV‐2 and Associated Mutants through Virucidal Inhibition and 3CL Protease Inactivation
Tang, H., Qin, H., He, S., Li, Q., Xu, H., Sun, M., Li, J., Lu, S., Luo, S., Mao, P., et al. (2023) · Advanced Science · doi:10.1002/advs.202207098 · Cited by 8
Maternal and Perinatal Outcomes of SARS-CoV-2 and Variants in Pregnancy
Feng, Q., Cui, Q., Xiao, Z., Liu, Z., & Fan, S. (2023) · Maternal-Fetal Medicine · doi:10.1097/fm9.0000000000000189 · Cited by 9
Early detection of emerging SARS-CoV-2 variants of interest for experimental evaluation
Wallace, Z. S., Davis, J. J., Niewiadomska, A. M., Olson, R., Shukla, M. P., Stevens, R. L., Zhang, Y., Zmasek, C. M., & Scheuermann, R. H. (2022) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2022.1020189 · Cited by 8
Self-citation
Coronavirus Disease 2019 Vaccination During Pregnancy and Breastfeeding: A Review of Evidence and Current Recommendations in Europe, North America, and Australasia
Pietrasanta, C., Ronchi, A., Crippa, B. L., Artieri, G., Ballerini, C., Crimi, R., Mosca, F., & Pugni, L. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.883953 · Cited by 8
A quadri-fluorescence SARS-CoV-2 pseudovirus system for efficient antigenic characterization of multiple circulating variants
Chen, J., Huang, Z., Xiao, J., Du, S., Bu, Q., Guo, H., Ye, J., Chen, S., Gao, J., Li, Z., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100856 · Cited by 7
A high-throughput SARS-CoV-2 pseudovirus multiplex neutralization assay
Sievers, B. L., Gelbart, T., & Tan, G. S. (2022) · STAR Protocols · doi:10.1016/j.xpro.2022.101835 · Cited by 7
Self-citation
Evolutionary trajectory of receptor binding specificity and promiscuity of the spike protein of SARS‐CoV ‐2
Planchais, C., Reyes‐Ruiz, A., Lacombe, R. V., Zarantonello, A., Lecerf, M., Revel, M., Roumenina, L. T., Atanasov, B. P., Mouquet, H., & Dimitrov, J. D. (2022) · Protein Science · doi:10.1002/pro.4447 · Cited by 7
Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti–SARS-CoV-2 antibodies in the absence of CXCL13
Azarias-da-Silva, M., Nioche, P., Soudaramourty, C., Bull-Maurer, A., Tiouajni, M., Kong, D., Zghidi‐Abouzid, O., Picard, M., Mendes‐Frias, A., Cruz, A. S., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg2122 · Cited by 6
An in silico drug repurposing pipeline to identify drugs with the potential to inhibit SARS-CoV-2 replication
MacMahon, M., Hwang, W., Yim, S., MacMahon, E., Abraham, A., Barton, J., Tharmakulasingam, M., Bilokon, P., Gaddi, V. P., & Han, N. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101387 · Cited by 6
A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model
Ma, J., Liu, X., Zhou, M., Chen, P., Chen, R., Wang, J., Zhu, H., Wu, K., Ye, J., Zhang, Y., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01684-22 · Cited by 6
Synthetic Analogs of the Sponge Sesterterpenoid Alotaketal C are Potent Inhibitors of SARS-CoV-2 Omicron BA.1 and BA.5 Infections of Human Lung Cells
Blagojević, P. D., Pérez‐Vargas, J., Jian, K., Williams, D. E., Villanueva, I., Thompson, C. A. H., Ennis, S., Niikura, M., Tietjen, I., Jean, F., et al. (2023) · Organic Letters · doi:10.1021/acs.orglett.3c01536 · Cited by 6
De Novo Design of Lipopeptide‐Based β‐Sheet‐Like Self‐Assemblies: A Strategy to Develop Fusion Inhibitors as Broad‐Spectrum Antivirals
Sardar, A., Bhowmick, S., Kamble, M., Dewangan, N., Hazra, B., Mallick, A. I., & Tarafdar, P. K. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202403039 · Cited by 6
Effect of the incremental protection of previous infection against Omicron infection among individuals with a hybrid of infection- and vaccine-induced immunity: a population-based cohort study in Canada
Wu, S., Li, Y., Mishra, S., Bodner, K., Baral, S., Kwong, J. C., & Wei, X. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.11.028 · Cited by 6
Neutralizing and binding antibody responses to SARS-CoV-2 with hybrid immunity in pregnancy
Li, L., Matsui, Y., Prahl, M. K., Cassidy, A. G., Golan, Y., Jigmeddagva, U., Özarslan, N., Lin, C. Y., Buarpung, S., Gonzalez, V. J., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00948-3 · Cited by 5
Self-citation
SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition
Walker, M. R., Podlekareva, D. N., Johnsen, S., Leerhøy, B., Fougeroux, C. E., Søgaard, M., Salanti, A., Ditlev, S. B., & Barfod, L. K. (2022) · Viruses · doi:10.3390/v14091861 · Cited by 5
Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection
Pidal, P., Fernández, J. O., Airola, C., Araujo, M., Menjiba, A. M., Martín, H. S., Bruneau, N., Balanda, M., Elgueta, C., Fasce, R., et al. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00753-6 · Cited by 5
Effective cellular and neutralizing immunity against SARS-CoV-2 after mRNA booster vaccination is associated with pDC and B cell activation
Fabricius, D., Ludwig, C., Proffen, M., Hägele, J., Scholz, J. A. M., Vieweg, C., Rode, I., Hoffmann, S., Körper, S., Schrezenmeier, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1580448 · Cited by 4
RNA vaccines for cancer: revolutionizing immunization strategies
Huang, D., Zhang, J., Zeng, X., Zhang, Y., & Song, E. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.09.003 · Cited by 4
Would New SARS-CoV-2 Variants Change the War against COVID-19?
Redwan, E. M. M. M., Elrashdy, F., Aljabali, A. A. A., Baetas‐da‐Cruz, W., Barh, D., Brufsky, A., Hassan, S. S., Lundstrom, K. H., Serrano‐Aroca, Á., Takayama, K., et al. (2022) · Epidemiologia · doi:10.3390/epidemiologia3020018 · Cited by 4
Does COVID-19 vaccination still have a role in maternal and perinatal outcomes during the Omicron era? A multicentre observational study
Jarraya, A., Kammoun, M., Kanoun, M., Derbel, M., Sansa, H., Chaaben, K., & Kolsi, K. (2022) · Italian Journal of Gynaecology and Obstetrics · doi:10.36129/jog.2022.85 · Cited by 4
Pregnancy and lactation induce distinct immune responses to COVID-19 booster vaccination and SARS-CoV-2 breakthrough infection
Yin, K., Li, L., Luo, X., Neidleman, J. A., Cassidy, A. G., Golan, Y., Özarslan, N., Lin, C. Y., Jigmeddagva, U., Ilala, M., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.191930 · Cited by 3
Self-citation
Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents
Wang, H., Yu, Y., Wu, B., Xiao, M., Wang, Z., Diao, T., Zeng, R., Chen, L., Lei, Y., Long, P., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-022-0954-x · Cited by 3
Key β1-4 galactosylated glycan receptors of SARS-CoV-2 and its inhibitor from the galactosylated glycoproteins of bovine milk
Yu, H., Chen, W., Shu, J. H., Wu, X., Quan, J., Cheng, H., Bao, X., Wu, D., Wang, X., & Li, Z. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.010 · Cited by 2
Patterns and functional consequences of antibody speciation in maternal-fetal transfer of coronavirus-specific humoral immunity
Hederman, A. P., Brookes, H. M., Natarajan, H., Heyndríckx, L., Ariën, K. K., Weiner, J. A., Rottenstreich, A., Zarbiv, G., Wolf, D. G., Goetghebuer, T., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013408 · Cited by 2
Diterpenoids target SARS-CoV-2 RdRp from the roots of Euphorbia fischeriana Steud
Ruan, T., Xiang, Z.-R., Zhang, Y.-W., Fan, S.-R., Ren, J., Zhao, Q., Sun, X.-L., Wu, S.-L., Xu, L., Qiao, M., et al. (2024) · Frontiers in Plant Science · doi:10.3389/fpls.2024.1425759 · Cited by 2
Construction and immunogenicity of recombinant Lactiplantibacillus plantarum vaccine candidate expressing SARS-CoV-2 Omicron S1 protein
Zhang, G., Hao, J., Li, L., Jiang, Y., Hao, P., Yu, J., Ren, L., Li, C., & Wang, M. (2025) · Animals and zoonoses. · doi:10.1016/j.azn.2025.02.001 · Cited by 2
Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants
Jia, L., Zhou, Y., Li, S., Zhang, Y., Yan, D., Wang, W., Zhang, W., Wan, Y., & Qiu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.897879 · Cited by 2
Saúde da Mulher - Edição XXI
Freitas, G. B. L. D., & Resende, A. F. P. (2025) · doi:10.59290/978-65-6029-200-0 · Cited by 1
Neutralization and ADCC reveal divergent spike-subdomain targeting across SARS-CoV-2 vaccine platforms in an African cohort
Oluka, G. K., Katende, J. S., Kato, L., Ankunda, V., Sembera, J., Ejou, P., Odoch, G., Namuyanja, A., Kaleebu, P., & Serwanga, J. (2025) · iScience · doi:10.1016/j.isci.2025.114351 · Cited by 1
Dual induction of tissue-resident T and B cell immunity for broad influenza protection with a nanofiber-VLP vaccine
Wang, X., Luo, H., Fan, Z., Xie, R., Liu, S., Pan, Q., Zhang, Z., Yan, F., Li, J., Yang, C., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04349-7 · Cited by 1
Structural and functional dissection of neutralisation differences among SARS-CoV-2 variants using antigenicity prediction and CR3022 binding analysis
Sawant, J., Patil, A. A., Thakar, M. R., & Kurle, S. N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1810369 · Cited by 1
Brixia and qSOFA Scores, Coagulation Factors and Blood Values in Spring versus Autumn 2021 Infection in Pregnant Critical COVID-19 Patients: A Preliminary Study
Filip, C., Covali, R. A., Socolov, D. G., Akad, M., Cărăuleanu, A., Vasilache, I.-A., Scripcariu, I. S., Păvăleanu, I., Buţureanu, T., Ciuhodaru, M., et al. (2022) · Healthcare · doi:10.3390/healthcare10081423 · Cited by 1
Isolation of SARS-CoV-2-blocking recombinant antibody fragments and characterisation of their binding to variant spike proteins
Antoine, D., Mohammadi, M., McDermott, C. E., Walsh, E., Johnson, P. A., Wawrousek, K., & Wall, J. G. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2022.1028186 · Cited by 1
How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?
Giovannoni, G. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103803 · Cited by 1
Robust T Cell Responses to the Pfizer/Biontech Vaccine Compared to Infection and Evidence of Attenuated Cd8+ T Cell Responses Due to Covid-19Preprint
Gao, F., Mallajoysula, V., Arunachalam, P. S., Manohar, M., Röltgen, K., Yang, F., Wirz, O. F., Hoh, R. A., Haraguchi, E., Lee, J.-Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4173451 · Cited by 1
Self-citation
Bovine milk glycoproteins inhibit SARS-CoV-2 and influenza virus co-infectionPreprint
Yu, H., Chen, W., Shu, J. H., Wu, X., Quan, J., Cheng, H., Bao, X., Wu, D., Wang, X., & Li, Z. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.20.529234 · Cited by 1
Cytokinesis in plant cells and the role of the cytoskeleton
Valster, A. H. (2000) · ScholarWorks@UMassAmherst (University of Massachusetts Amherst)
Precisiones sobre el artículo “Conocimientos, actitudes y percepción sobre el rol de los medios de comunicación respecto a la COVID-19 en estudiantes de Medicina de una universidad peruana”
Zamora, J. A. G. (2022) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2022.392.11071

Authors: Sievers, B. L., Chakraborty, S., Xue, Y., Gelbart, T., Gonzalez, J. C., Cassidy, A. G., Golan, Y., Prahl, M., Gaw, S. L., Arunachalam, P. S., Blish, C. A., Boyd, S. D., Davis, M. M., Jagannathan, P., Nadeau, K. C., Pulendran, B., Singh, U., Scheuermann, R. H., Frieman, M. B., Vashee, S., Wang, T. T., & Tan, G. S.
Affiliations: J. Craig Venter Institute (US)
Stanford Medicine (US)
Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
University of California, San Francisco (US)
Chan Zuckerberg Biohub San Francisco (US)
Howard Hughes Medical Institute (US)
University of Maryland, Baltimore (US)
Corresponding author: Wang, Taia T.
Tan, Gene S.
ORCID: Sievers, Benjamin L.
Chakraborty, Saborni
Xue, Yong
Gelbart, Terri
Gonzalez, Joseph C.
Cassidy, Arianna G.
Golan, Yarden
Prahl, Mary
Gaw, Stephanie L.
Arunachalam, Prabhu S.
Blish, Catherine A.
Boyd, Scott D.
Davis, Mark M.
Jagannathan, Prasanna
Nadeau, Kari C.
Pulendran, Bali
Singh, Upinder
Scheuermann, Richard H.
Frieman, Matthew B.
Vashee, Sanjay
Wang, Taia T.
Tan, Gene S.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2022-03-02
Volume: 14
Issue: 634
Pages: eabn7842-eabn7842
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.abn7842
PMC: PMC8891085
OpenAlex: W4205576941
Cited by: 111
References: 35
Citations by year: 2026: 3 · 2025: 10 · 2024: 10 · 2023: 24 · 2022: 63
FWCI: 13.30
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
Locations: Science Translational Medicine (publishedVersion, cc-by)
medRxiv (acceptedVersion)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion, cc-by)
ImmPort
Funders: Sanofi
Gilead Sciences
Thomas Jefferson University
Regeneron Pharmaceuticals
Fast Grants
National Institutes of Health (75N93019C00076, HHSN272201400008C, ASPR-20-01495)
Biomedical Advanced Research and Development Authority (ASPR-20-01495)
National Cancer Institute (U54CA260517)
National Institute of Allergy and Infectious Diseases (HHSN272201400008C), R03AI146632, 75N93019C00076, R01AI137365, U01AI150741, K23AI076614, U19AI111825, K23AI127886, U19AI057229, P01AI153559, U19AI167903, T32AI007290, K24AI144048)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords: SARS-CoV-2, Omicron variant, Beta variant, Delta variant, neutralizing antibodies, mRNA vaccines, natural infection, antibody escape, booster vaccination, pregnant women, spike protein mutations, vaccine response heterogeneity
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, Adult, Antibodies, Viral, Female, Humans, Pregnancy, Pregnancy Complications, Infectious, Vaccines, Synthetic, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks